Nasdaq-listed biopharmaceutical firm China Biologic Products Holdings suspended the trading of its shares on Wall Street on Wednesday, after the completion of a take-private deal sponsored by a Chinese buyout group that valued the firm at about $4.76 billion.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
